European Journal of Cancer最新文献

{"title":"Corrigendum to “Epithelial head and neck cancer survival in Europe: Geographical variation, time trends and long term survival” Eur J Cancer 229 (October) (2025) 115692","authors":"G. Gatta , S. Luttmann , A. Trama , S. Rossi , J. Galceran , K. Innos , M. Guevara , L. Licitra , D. Bennet , D. Redondo-Sánchez , R. Capocaccia","doi":"10.1016/j.ejca.2025.116147","DOIUrl":"10.1016/j.ejca.2025.116147","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116147"},"PeriodicalIF":7.1,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19)","authors":"Alfredo Addeo ,&nbsp;Daniel Dietrich ,&nbsp;Nicolas Mach ,&nbsp;Michael Thomas Mark ,&nbsp;Markus Joerger ,&nbsp;Patrizia Froesch ,&nbsp;Martina Imbimbo ,&nbsp;David König ,&nbsp;Eugenio Fernandez ,&nbsp;Annalea Patzen ,&nbsp;Hansjörg Vees ,&nbsp;Cristina Picardi ,&nbsp;Martin Früh","doi":"10.1016/j.ejca.2025.116138","DOIUrl":"10.1016/j.ejca.2025.116138","url":null,"abstract":"<div><h3>Background</h3><div>Small cell lung cancer (SCLC) is an aggressive tumour type accounting for 10–15 % of lung cancers. The role of thoracic radiotherapy (TRT) in extensive stage SCLC (ES_SCLC) in the era of checkpoint inhibitors (CPIs) is undefined.</div></div><div><h3>Methods</h3><div>SAKK 15–19 is a national, multicenter, single-arm prospective phase II study evaluating consolidative TRT after standard first-line chemotherapy plus durvalumab in ES-SCLC. Patients (pts) with confirmed ES-SCLC and ECOG ≤ 1 received carboplatin AUC5 (day 1), etoposide 100 mg/m² (days 1–3) and durvalumab 1500 mg (day 1) for 4 cycles, followed by maintenance durvalumab every 4 weeks for up to 2 years in pts without progression. TRT (39 Gy in 13 fractions over 2.5 weeks) was delivered within 5 weeks after chemoimmunotherapy. Prophylactic cranial irradiation was permitted. The primary endpoint was 12-month progression-free rate (PFR); secondary endpoints included progression-free survival (PFS), response rate and overall survival (OS). The study aimed at a 12-month PFR ≥ 25 % (H1) vs. ≤ 12.5 %.</div></div><div><h3>Results</h3><div>Forty-six pts were enrolled; 37 % had ECOG 0, 30 % had asymptomatic brain metastases. At 29-month follow-up, the 12-month PFR was 15.6 (95 % CI 7–27.5), median PFS 6.4 months (95 % CI 4.8–7.2) and median OS 15.0 months (95 % CI 10.2–22.0). Grade 3–4 treatment-related adverse events (TRAEs) occurred in 23.9 % of pts, mainly neutropenia (23.9 %) and thrombocytopenia (8.4 %). One pt (2 %) had grade 5 sepsis; no severe TRT-related toxicities were observed.</div></div><div><h3>Conclusions</h3><div>Adding consolidative TRT after chemotherapy plus durvalumab in ES-SCLC didn’t meet the primary endpoint of the expected 12-month PFR. No additional severe toxicities from TRT were observed. Ongoing larger Phase III trials, including RAPTOR (LNRG LU007), will further define TRT’s role in this setting.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116138"},"PeriodicalIF":7.1,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: “Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis” [Eur J Cancer 145 (2021) 197–209]","authors":"Angela Esposito ,&nbsp;Antonio Marra ,&nbsp;Vincenzo Bagnardi ,&nbsp;Samuele Frassoni ,&nbsp;Stefania Morganti ,&nbsp;Giulia Viale ,&nbsp;Paola Zagami ,&nbsp;Gianluca M. Varano ,&nbsp;Giorgio Buccimazza ,&nbsp;Franco Orsi ,&nbsp;Konstantinos Venetis ,&nbsp;Luca Mazzarella ,&nbsp;Giuseppe Viale ,&nbsp;Nicola Fusco ,&nbsp;Carmen Criscitiello ,&nbsp;Giuseppe Curigliano","doi":"10.1016/j.ejca.2025.116107","DOIUrl":"10.1016/j.ejca.2025.116107","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116107"},"PeriodicalIF":7.1,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment","authors":"Mélanie Debiais ,&nbsp;Anthony Tarabay ,&nbsp;Sarah Blanchet-Deverly ,&nbsp;Géraldine M. Camilleri ,&nbsp;Alexandre Megherbi ,&nbsp;Laura Diebakate ,&nbsp;Maxime Collin ,&nbsp;Antoine Hollebecque ,&nbsp;Cristina Smolenschi ,&nbsp;Marine Valéry ,&nbsp;Thomas Pudlarz ,&nbsp;Alina Cristina Fuerea ,&nbsp;Valérie Boige ,&nbsp;Michel Ducreux ,&nbsp;Alice Boilève","doi":"10.1016/j.ejca.2025.116160","DOIUrl":"10.1016/j.ejca.2025.116160","url":null,"abstract":"<div><h3>Background</h3><div>Metastatic pancreatic adenocarcinoma (mPDAC) has a poor prognosis. FOLFIRINOX (FFX) and gemcitabine nab-paclitaxel (GN) are the preferred first line (L1) regimens. We evaluated real-world outcomes of L1 therapies.</div></div><div><h3>Methods</h3><div>Retrospective analysis of all patients who received L1 chemotherapy for mPDAC between 2010 and 2024 at a single academic comprehensive cancer center.</div></div><div><h3>Results</h3><div>A total of 1012 patients were included: 48 % women, median age 63 years, 91 % ECOG 0–1. Synchronous metastases occurred in 66 % of patients. Liver (67 %), lung (20 %) and peritoneum (20 %) were the most frequent sites of metastasis.</div><div>L1 regimens were FFX (n = 621, 61 %), gemcitabine (Gem) (141, 14 %), GN (78, 8 %), and others (n = 172, 17 %). Compared with GN, FFX recipients were younger (61 vs 65 years, p &lt; 0.0001) with better ECOG (≥ 2 in 4 % vs 13 %, p &lt; 0.0001).</div><div>Median OS was 14.5 months (95 %CI [13.3–15.8]) with FFX, 12.4 [9.4–21.9] with GN, 7.9 [6.5–10.7] with Gem and 9.2 [7.2–13.1] with others (p &lt; 0.0001). Respective median PFS were 7.0 months [95 %CI: 6.5–7.9], 5.4 [4.0–8.3], 4.9 [3.6–6.0] and 5.6 [3.6–7.0] (p &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>In this large real-world cohort, FFX was associated with superior response rate, PFS, and OS compared with other L1 regimens, supporting its use as standard first-line therapy for mPDAC.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116160"},"PeriodicalIF":7.1,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Waldenström’s macroglobulinemia: The LYSA pragmatic guidelines","authors":"Damien Roos-Weil ,&nbsp;Cécile Tomowiak ,&nbsp;Stéphanie Poulain ,&nbsp;Florence Nguyen-Khac ,&nbsp;Florian Bouclet ,&nbsp;Marine Armand ,&nbsp;Thérèse Aurran ,&nbsp;Eric Durot ,&nbsp;David Ghez ,&nbsp;Bénédicte Hivert ,&nbsp;Kamel Laribi ,&nbsp;Magali Le Garff Tavernier ,&nbsp;Stéphane Lepretre ,&nbsp;Lydia Montes ,&nbsp;Amine Moslemi ,&nbsp;Laurence Simon ,&nbsp;Véronique Leblond ,&nbsp;Pierre Morel ,&nbsp;Olivier Tournilhac","doi":"10.1016/j.ejca.2025.116120","DOIUrl":"10.1016/j.ejca.2025.116120","url":null,"abstract":"<div><div>Waldenström’s macroglobulinemia (WM) is a rare, indolent B-cell lymphoma that predominantly affects older adults. In recent years, significant progress has been made in understanding its pathogenesis, identifying relevant biomarkers, and developing novel therapeutic approaches to complement traditional chemoimmunotherapy—collectively reshaping the management landscape of WM. In this article, we provide comprehensive, evidence-based recommendations for the diagnosis, molecular evaluation, and treatment of WM, including strategies for both frontline and relapsed disease. These guidelines are informed by the latest clinical research, expert consensus, and current practice standards, with the goal of equipping clinicians with a practical and effective framework for delivering optimal care to patients with WM.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116120"},"PeriodicalIF":7.1,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter Re: Critical evaluation of sentinel lymph node biopsy in pT1b and pT2a melanoma patients: A nationwide population-based study","authors":"Alexander HR Varey,&nbsp;Serigne N. Lo,&nbsp;John F. Thompson","doi":"10.1016/j.ejca.2025.116135","DOIUrl":"10.1016/j.ejca.2025.116135","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116135"},"PeriodicalIF":7.1,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145647785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer – A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial","authors":"Kathrin Heinrich ,&nbsp;Sebastian Stintzing ,&nbsp;Ludwig Fischer von Weikersthal ,&nbsp;Thomas Decker ,&nbsp;Alexander Kiani ,&nbsp;Florian Kaiser ,&nbsp;Salah-Eddin Al-Batran ,&nbsp;Tobias Heintges ,&nbsp;Christoph Lerchenmüller ,&nbsp;Christoph Kahl ,&nbsp;Gernot Seipelt ,&nbsp;Frank Kullmann ,&nbsp;Markus Moehler ,&nbsp;Werner Scheithauer ,&nbsp;Andreas Jung ,&nbsp;Julian W. Holch ,&nbsp;Swantje Held ,&nbsp;Dominik Paul Modest ,&nbsp;Volker Heinemann","doi":"10.1016/j.ejca.2025.116133","DOIUrl":"10.1016/j.ejca.2025.116133","url":null,"abstract":"<div><h3>Background</h3><div>Clinical trials in metastatic colorectal cancer (mCRC) are usually conducted irrespectively of sex. However, differences relating to safety and efficacy in the treatment of mCRC between male and female patients are of growing interest.</div></div><div><h3>Methods</h3><div>The randomized FIRE-3 study compared first-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) plus cetuximab to FOLFIRI plus bevacizumab in patients with <em>RAS</em> wildtype (<em>RAS</em> WT) mCRC. The present analysis focusses on the impact of sex and primary tumor (PT) sidedness on outcome parameters.</div></div><div><h3>Results</h3><div>Of 352 patients with <em>RAS</em> WT tumors, 249 (71 %) were male and 103 (29 %) female.</div><div>In male patients with left-sided <em>RAS/BRAF</em> WT tumors, a significant benefit from cetuximab was noted with regard to ORR (OR 1.15; P = 0.035) and OS (0.66; P = 0.010), while in right-sided patients cetuximab improved ORR (OR 2.92) and had no significant effect on PFS or OS.</div><div>In female patients with left-sided, <em>RAS/BRAF</em> WT PT, a comparable effect of cetuximab versus bevacizumab was observed with regard to ORR (OR 1.05; P &gt; 0.999), while a numerical OS benefit was noted in the cetuximab-arm (HR 0.78; P = 0.385).</div><div>By contrast, in female patients with right-sided PT, a clearly detrimental effect of cetuximab-based therapy was observed for ORR (OR 0.44; P = 0.617), PFS (HR 4.95; P = 0.005), and OS (HR 2.58; P = 0.080).</div><div>In the bevacizumab arm, neutropenia grade ≥ 3 was more frequent in female versus male patients (30.6 % versus 18.3 %; P = 0.063). Otherwise, there was no significant difference of grade ≥ 3 adverse events between male and female patients.</div></div><div><h3>Conclusions</h3><div>The exploratory analysis of FIRE-3 suggests that the efficacy of cetuximab combined with FOLFIRI in <em>RAS</em> wild-type mCRC is related to sex and primary tumor sidedness. The results support the inclusion of patient sex into the design of future trials.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116133"},"PeriodicalIF":7.1,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI performance for nodule volume doubling time in the follow-up of the UKLS lung cancer screening study compared to expert consensus and histological validation","authors":"Beibei Jiang ,&nbsp;Harriet L. Lancaster ,&nbsp;Michael P.A. Davies ,&nbsp;Jan-Willem C. Gratama ,&nbsp;Mario Silva ,&nbsp;Daiwei Han ,&nbsp;Jaeyoun Yi ,&nbsp;Carlijn M. van der Aalst ,&nbsp;Anand Devaraj ,&nbsp;Marjolein A. Heuvelmans ,&nbsp;John K. Field ,&nbsp;Matthijs Oudkerk","doi":"10.1016/j.ejca.2025.116137","DOIUrl":"10.1016/j.ejca.2025.116137","url":null,"abstract":"<div><h3>Aim</h3><div>To validate an artificial intelligence (AI) software for automated assessment of nodule growth by volume doubling time measurement (VDT) on protocol-mandated follow-up low-dose CT (LDCT) scans from the UK lung cancer screening (UKLS) trial.</div></div><div><h3>Methods</h3><div>This validation study included 710 UKLS participants with 939 LDCT follow-up scans (361 3-month and 578 12-month). Follow-up scans were assessed independently by both AI and human readers. A positive finding warranting referral was defined as the largest nodule with a solid component ≥ 100 mm³ showing VDT ≤ 400 days at follow-up. Performance was benchmarked against the European expert panel (reference standard) and then the histological outcomes (gold standard).</div></div><div><h3>Results</h3><div>Against the expert panel, AI achieved the lowest 3-month negative misclassification (NM) rate (1/11, 9.1 %), versus human readers (range: 18.2–63.6 %). AI’s positive misclassification (PM) rate was initially 7.8 % (28/361) at 3 months but decreased to 0.9 % (5/578) at 12 months. Against histological outcomes of 9 screen-detected lung cancers, AI identified VDT ≤ 400 days in all 4 cancers also deemed positive by the expert panel at the earliest 3-month follow-up, while human readers missed or delayed referrals in 1–3 of these. AI also identified VDT ≤ 400 days in 3 of 5 cancers that the panel classified as negative, primarily due to their sub-threshold volume (&lt;100mm³).</div></div><div><h3>Conclusions</h3><div>The automated AI system showed strong VDT assessment performance in follow-up screening, outperforming human readers in the early identification of rapid growth in histologically-confirmed cancers, thus supporting its potential to enhance risk stratification and facilitate earlier lung cancer detection.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116137"},"PeriodicalIF":7.1,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter Re: Critical evaluation of sentinel lymph node biopsy in pT1b and pT2a melanoma patients: A nationwide population-based study","authors":"Antonius W. Schurink,&nbsp;Robert C. Stassen,&nbsp;Astrid A.M. van der Veldt,&nbsp;Dirk J. Grünhagen","doi":"10.1016/j.ejca.2025.116136","DOIUrl":"10.1016/j.ejca.2025.116136","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116136"},"PeriodicalIF":7.1,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145647791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facilitating the interpretation of the multidimensional EORTC QLQ-FA12 fatigue questionnaire: Establishing thresholds for clinical importance","authors":"Patricia Blickle ,&nbsp;Lisa M. Storz ,&nbsp;Martina E. Schmidt ,&nbsp;Jens Lehmann ,&nbsp;Micha J. Pilz ,&nbsp;Marlena Milzer ,&nbsp;Imad Maatouk ,&nbsp;Johannes M. Giesinger ,&nbsp;Karen Steindorf","doi":"10.1016/j.ejca.2025.116134","DOIUrl":"10.1016/j.ejca.2025.116134","url":null,"abstract":"<div><h3>Objective</h3><div>Cancer-related fatigue is among the most burdensome side-effects of cancer and its treatment. The Fatigue Questionnaire of the European Organization for Research and Treatment of Cancer (EORTC QLQ-FA12) is a widely used measure to assess fatigue multidimensionally. However, interpretation of its scores can be challenging. Therefore, thresholds for clinical importance (TCI) for the three fatigue dimensions assessed by this questionnaire were developed.</div></div><div><h3>Methods</h3><div>A standardized approach was followed for the derivation of TCI. Three anchor items regarding limitations in daily life, need for help/care, and worries to the patient, their partner and/or family were completed by patients with various cancer types, in addition to the EORTC QLQ-FA12. Receiver Operating Characteristic curves and Youden's J were estimated to determine the most suitable TCIs.</div></div><div><h3>Results</h3><div>Complete data of the EORTC QLQ-FA12 and the anchor items were available for <em>N</em> = 1111 patients (age 67.2 ± 12.6 years; 61.2 % female) from two observational studies. The derived TCIs for the physical, emotional, and cognitive fatigue scores (scale 0–100) were 43, 28, and 25, respectively. Subgroup analyses, categorized by gender and age, yielded consistent results. The sensitivity of the thresholds ranged from 0.87 to 0.94; the specificity from 0.67 to 0.80. Areas under the curve were all ≥ 0.89.</div></div><div><h3>Conclusion</h3><div>The analyses established TCIs for the three dimensions of the EORTC QLQ-FA12. TCIs can be used in research and clinical practice to facilitate interpretation of individual patient scores at a single point in time. TCIs may indicate which patients experience a fatigue level that warrants additional clinical attention.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"232 ","pages":"Article 116134"},"PeriodicalIF":7.1,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}